PMID- 10679801
OWN - NLM
STAT- MEDLINE
DCOM- 20000310
LR  - 20190822
IS  - 0361-8609 (Print)
IS  - 0361-8609 (Linking)
VI  - 63
IP  - 3
DP  - 2000 Mar
TI  - Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) 
      regimen in refractory multiple myeloma: an International Oncology Study Group 
      (IOSG) phase II protocol.
PG  - 125-30
AB  - A 4- day continuous intravenous (CIV) infusion of vincristine and doxorubicin 
      with high-dose dexamethasone (VAD) regimen is a standard refractory multiple 
      myeloma (MM) regimen. A Phase II study of a CEVAD regimen, i.e., VAD plus 
      etoposide administered as a 96-hr continuous infusion, was carried out with IV 
      bolus cyclophosphamide. Thirty-six patients were treated on study and received a 
      total of 114 cycles of CEVAD: median 2 cycles (range 1-8). No patient achieved a 
      CR. The overall rate of PR was 15/36 (42%). Patients achieved maximal response 
      after a median of 4 (range 3-6) courses. PR rates were 40% (4/10) in patients 
      with primary refractory disease, 48% (11/23) in patients with secondary 
      refractory disease, 31% (6/19) in patients who had failed previous VAD therapy, 
      and 50% (7/14) in patients receiving 2nd or subsequent relapse therapy. Three 
      patients died during their initial cycle of therapy from rapidly progressive 
      disease and sepsis. Overall median survival was 24 weeks with a 1-year survival 
      of 33.3%  inverted question mark95% confidence interval of 20-46% inverted question mark. Myelosuppression was the most 
      frequent adverse event with NCI grade 2 neutropenia and/or thrombocytopenia in 
      15% of first cycles, grade 3 in 20%, and grade 4 in 65%. Two-thirds of patients 
      had at least one episode of grade 3 or 4 sepsis. In 15% of septic episodes 
      positive blood cultures were obtained. Overt cardiotoxicity was seen in two 
      patients. CEVAD as used in this study was not more effective than VAD in terms of 
      overall response rate or survival.
CI  - Copyright 2000 Wiley-Liss, Inc.
FAU - Giles, F J
AU  - Giles FJ
AD  - The International Oncology Study Group, Houston, Texas 77401, USA. 
      frankgiles@aol.com
FAU - Wickham, N R
AU  - Wickham NR
FAU - Rapoport, B L
AU  - Rapoport BL
FAU - Somlo, G
AU  - Somlo G
FAU - Lim, S W
AU  - Lim SW
FAU - Shan, J
AU  - Shan J
FAU - Lynott, A M
AU  - Lynott AM
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 5J49Q6B70F (Vincristine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 80168379AG (Doxorubicin)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - CEVAD protocol
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Cyclophosphamide/administration & dosage
MH  - Dexamethasone/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Drug Administration Schedule
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*drug therapy
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage
EDAT- 2000/02/19 09:00
MHDA- 2000/03/18 09:00
CRDT- 2000/02/19 09:00
PHST- 2000/02/19 09:00 [pubmed]
PHST- 2000/03/18 09:00 [medline]
PHST- 2000/02/19 09:00 [entrez]
AID - 10.1002/(SICI)1096-8652(200003)63:3<125::AID-AJH3>3.0.CO;2-S [pii]
AID - 10.1002/(sici)1096-8652(200003)63:3<125::aid-ajh3>3.0.co;2-s [doi]
PST - ppublish
SO  - Am J Hematol. 2000 Mar;63(3):125-30. doi: 
      10.1002/(sici)1096-8652(200003)63:3<125::aid-ajh3>3.0.co;2-s.